1. Home
  2. Analysis
  3. Dopar
  4. Requip

Dopar vs. Requip: side effect and effectiveness comparison (a real world drug study)

Summary:

We compare the side effects and drug effectiveness of Dopar and Requip. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 52,728 people who take Dopar and Requip, and is updated regularly.

What is Dopar?

Dopar has active ingredients of levodopa. It is often used in parkinson's disease. eHealthMe is studying from 111 Dopar users. Check the latest studies of Dopar.

What is Requip?

Requip has active ingredients of ropinirole hydrochloride. It is often used in restless leg syndrome. eHealthMe is studying from 22,950 Requip users. Check the latest studies of Requip.

On Jun, 11, 2026

52,728 people who take Dopar and Requip are studied.

Dopar vs Requip drug comparison reports.

Drugs being compared in this study:

  • Dopar (levodopa)
  • Requip (ropinirole hydrochloride)

Most common side effects of the drugs, overall:

Click here to view

Most common side effects of the drugs, in long term (1+ years) use:

Click here to view

Drug effectiveness:

Dopar:

  • not at all: 4.35 %
  • somewhat: 13.04 %
  • moderate: 34.78 %
  • high: 43.48 %
  • very high: 4.35 %

Requip:

  • not at all: 2.84 %
  • somewhat: 16.26 %
  • moderate: 29.83 %
  • high: 35.05 %
  • very high: 16.03 %

Want to compare Dopar with Requip?

- Personalize this study to your gender and age (0-99+)

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Alternative drugs to, pros and cons of:

Browse all side effects of Dopar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Requip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study is based on levodopa and ropinirole hydrochloride (the active ingredients of Dopar and Requip, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.